Evidence map›Paper›PMID 37267670›Full record

Trial reportPsychiatry research2023

Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophrenia.

Jessica A Wojtalik, Wilson J Brown, Raquelle I Mesholam-Gately, Anju Kotwani, Matcheri S Keshavan, Shaun M Eack

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Psychiatry research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jessica A WojtalikJack, Joseph and Morton Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, USA. Electronic address: jaw317@case.edu.
Wilson J BrownDepartment of Psychology, School of Humanities and Social Sciences, Pennsylvania State University, The Behrend College, Erie, PA, USA.
Raquelle I Mesholam-GatelyDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center Division of Public Psychiatry, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Anju KotwaniJack, Joseph and Morton Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, USA.
Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center Division of Public Psychiatry, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Shaun M EackSchool of Social Work, University of Pittsburgh, Pittsburgh, PA, USW; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Funding

Brain Imaging, Cognitive Enhancement and Early SchizophreniaR01MH092440 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KESHAVAN, MATCHERI S. · 2012 to 2016
$3.1M
NIMH NIH HHS R01 MH092440
6 · The paper itself

Abstract

Treatment discontinuation during clinical trials in schizophrenia is a critical challenge, especially for longer-term interventions in the early course. This research explored predictors of treatment discontinuation in an outpatient early course schizophrenia sample (N = 102) during an 18-month multi-site trial of Cognitive Enhancement Therapy (n = 58) and Enriched Supportive Therapy (n = 44). Fifty-three (52%) participants discontinued, with no significant difference between the treatment groups in discontinuation rate. Univariate and multivariate binary logistic regression models explored differences in key demographic and cognitive and behavioral outcomes between participants who completed and discontinued treatment. Significant multivariate predictors of discontinuation included IQ (linear) and problem solving (curvilinear). The concave shape of the problem solving prediction demonstrated that initially as scores were increasing the probability of non-completion was increasing. However, after a score of 41 (below average problem solving), the probability of being a non-completer decreased as performance increased. Non-completers had significantly lower IQ scores compared to completers. Post-hoc analyses indicated that participants who discontinued prior to mid-treatment exhibited the greatest intellectual challenges, with comparisons moderate-to-large in strength. IQ and problem solving are likely important factors to assess at pre-treatment in early course schizophrenia trials to identify those most vulnerable to discontinuation.

Indexed as

Cognitive Behavioral TherapySchizophreniaCognitionHumansClinical trialEarly courseIQProblem solvingPsychosocial treatmentSchizophreniaTreatment discontinuation

Identifiers

PMID37267670
PMCPMC10527356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.